AACR 2021: Evaluating anti-SIRPα in vivo efficacy in humanized B-NDG hSIRPA mice and B-NDG hSIRPA/hCD47 mice

AACR 2021: Evaluating anti-SIRPα in vivo efficacy in humanized B-NDG hSIRPA mice and B-NDG hSIRPA/hCD47 mice

• CD47 binding to SIRPA results in inhibitory signals that protect cancer cells from phagocytosis by macrophages and other myeloid cells. 
• Biocytogen generated humanized SIRPA and double humanized SIRPA/CD47 mouse models in our B-NDG immunodeficient background, which completely lack T cells, B cells, NK cells, and display cytokine signaling deficiencies. 
• Following tumor xenografting using Raji-Luc cells, anti-human SIRPA antibodies alone did not have an impact on tumor inhibition in vivo, which may be due to reduced stability of anti-human SIRPA antibodies observed in B-NDG hSIRPA/hCD47 mice. 
• Anti-human SIRPA and CD20 antibodies synergize to promote tumor inhibition in B-NDG hSIRPA/hCD47 mice.